FDA clears Hologic's APTIMA Trichomonas vaginalis Assay

Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System.

The APTIMA Trichomonas vaginalis Assay, first cleared for use on Hologic's TIGRIS System in April 2011, remains the only FDA-cleared amplified nucleic acid test on the market specifically cleared to detect Trichomonas vaginalis, the most common curable sexually transmitted infection in the United States. The assay may be used to test clinician-collected endocervical or vaginal swabs, and specimens collected in Hologic's ThinPrep vial from symptomatic or asymptomatic women.

"The PANTHER System is a world class automation solution for a broad range of laboratories," said Rob Cascella , President and Chief Executive Officer. "Expanding the menu of available assays on this system builds on our strategy of delivering workflow and revenue efficiencies to our laboratory partners. We are excited to have APTIMA trichomonas available on PANTHER and look forward to further expanding our menu with high-value assays over the next year and beyond."

Trichomonas is a sexually transmitted parasite estimated by the U.S. Centers for Disease Control to cause 7.4 million infections in the U.S. annually. Trichomonas vaginalis has been linked to several serious health outcomes including female infertility, pelvic inflammatory disease, premature births, low birth weight and increased risk of HIV transmission.

Current techniques for the diagnosis and screening of Trichomonas have limitations in comparison to nucleic acid testing. Most testing is currently done via culture methods, which are slow and less sensitive than molecular assays, or a "wet mount," which requires the microscopic examination of a sample shortly after it is collected and is even less sensitive than culture.

SOURCE Hologic, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hologic, Inc.. (2013, January 15). FDA clears Hologic's APTIMA Trichomonas vaginalis Assay. News-Medical. Retrieved on December 07, 2019 from https://www.news-medical.net/news/20130115/FDA-clears-Hologics-APTIMA-Trichomonas-vaginalis-Assay.aspx.

  • MLA

    Hologic, Inc.. "FDA clears Hologic's APTIMA Trichomonas vaginalis Assay". News-Medical. 07 December 2019. <https://www.news-medical.net/news/20130115/FDA-clears-Hologics-APTIMA-Trichomonas-vaginalis-Assay.aspx>.

  • Chicago

    Hologic, Inc.. "FDA clears Hologic's APTIMA Trichomonas vaginalis Assay". News-Medical. https://www.news-medical.net/news/20130115/FDA-clears-Hologics-APTIMA-Trichomonas-vaginalis-Assay.aspx. (accessed December 07, 2019).

  • Harvard

    Hologic, Inc.. 2013. FDA clears Hologic's APTIMA Trichomonas vaginalis Assay. News-Medical, viewed 07 December 2019, https://www.news-medical.net/news/20130115/FDA-clears-Hologics-APTIMA-Trichomonas-vaginalis-Assay.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Hologic first quarter revenues increase 9.3% to $472.7 million